The longest study to date of MS Copaxone infections, a 15 yr study in Jerusalem, was made public in February of 2010. The study data was published in the Multiple Sclerosis journal and chronicles the longest ever uninterrupted evaluation of Multiple Sclerosis Copaxone treatment involving relapsing-remitting multiple sclerosis patients to date. The decade and a half clinical study showed that over 80 percent of participants were still able to walk without help, even though they had MS for about 22 years. Furthermore, about 66% did not proceed to develop secondary-progressive MS. The ARR, or Annualized Relapse Rate, was also reduced. For those that remained on the MS Copaxone therapy for the duration of the study, the ARR declined from 1.12 to .25 by the end of the trial. The margin of error for ARR was plus or minus 0.82 and 0.34 respectively.
